Novartis to Acquire Avidity Biosciences for About $12B
Favicon 
www.newsmax.com

Novartis to Acquire Avidity Biosciences for About $12B

Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash. Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday.